ATE221083T1 - Glialmitogene faktoren, ihre herstellung und verwendung - Google Patents

Glialmitogene faktoren, ihre herstellung und verwendung

Info

Publication number
ATE221083T1
ATE221083T1 AT92907539T AT92907539T ATE221083T1 AT E221083 T1 ATE221083 T1 AT E221083T1 AT 92907539 T AT92907539 T AT 92907539T AT 92907539 T AT92907539 T AT 92907539T AT E221083 T1 ATE221083 T1 AT E221083T1
Authority
AT
Austria
Prior art keywords
factors
glialmitogenic
production
factor
new
Prior art date
Application number
AT92907539T
Other languages
English (en)
Inventor
Andrew David John Goodearl
Michael Derek Waterfield
Paul Stroobant
Luisa Minghetti
Mark Andrew Marchionni
Original Assignee
Ludwig Inst Cancer Res
Cambridge Neuroscience Res Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Inst Cancer Res, Cambridge Neuroscience Res Inc filed Critical Ludwig Inst Cancer Res
Application granted granted Critical
Publication of ATE221083T1 publication Critical patent/ATE221083T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT92907539T 1991-04-10 1992-04-03 Glialmitogene faktoren, ihre herstellung und verwendung ATE221083T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB919107566A GB9107566D0 (en) 1991-04-10 1991-04-10 Glial mitogenic factors,their preparation and use
PCT/GB1992/000595 WO1992018627A1 (en) 1991-04-10 1992-04-03 Glial mitogenic factors, their preparation and use

Publications (1)

Publication Number Publication Date
ATE221083T1 true ATE221083T1 (de) 2002-08-15

Family

ID=10692987

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92907539T ATE221083T1 (de) 1991-04-10 1992-04-03 Glialmitogene faktoren, ihre herstellung und verwendung

Country Status (13)

Country Link
EP (1) EP0579640B1 (de)
JP (1) JPH06507544A (de)
KR (1) KR100274305B1 (de)
AT (1) ATE221083T1 (de)
AU (2) AU1450992A (de)
CA (1) CA2108119C (de)
DE (1) DE69232693T2 (de)
DK (1) DK0579640T3 (de)
GB (1) GB9107566D0 (de)
IE (1) IE921062A1 (de)
PT (1) PT100344B (de)
WO (1) WO1992018627A1 (de)
ZA (1) ZA922441B (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530109A (en) * 1991-04-10 1996-06-25 Ludwig Institute For Cancer Research DNA encoding glial mitogenic factors
IL101943A0 (en) * 1991-05-24 1992-12-30 Genentech Inc Structure,production and use of heregulin
US5367060A (en) * 1991-05-24 1994-11-22 Genentech, Inc. Structure, production and use of heregulin
US5834229A (en) 1991-05-24 1998-11-10 Genentech, Inc. Nucleic acids vectors and host cells encoding and expressing heregulin 2-α
WO1994003644A1 (en) * 1992-08-10 1994-02-17 Cambridge Neuroscience, Inc. Inhibitors of cell proliferation, their preparation and use
GB9217316D0 (en) * 1992-08-14 1992-09-30 Ludwig Inst Cancer Res Schwann cell mitogenic factor,its preparation and use
US5770567A (en) * 1994-11-14 1998-06-23 Genentech, Inc. Sensory and motor neuron derived factor (SMDF)
US5721139A (en) * 1995-05-10 1998-02-24 Genentech, Inc. Isolating and culturing schwann cells
US5849585A (en) * 1995-05-10 1998-12-15 Genetech, Inc. Isolating and culturing Schwann cells
US6033660A (en) * 1995-05-10 2000-03-07 Genentech, Inc. Method of treating a nervous system injury with cultured schwann cells
US5912326A (en) * 1995-09-08 1999-06-15 President And Fellows Of Harvard College Cerebellum-derived growth factors
AU727606B2 (en) * 1996-07-12 2000-12-14 Genentech Inc. Gamma-heregulin
DE69840699D1 (de) 1997-02-10 2009-05-14 Genentech Inc Heregulin varianten
US6136558A (en) * 1997-02-10 2000-10-24 Genentech, Inc. Heregulin variants
WO1999031505A1 (en) * 1997-12-15 1999-06-24 Shire Laboratories Inc. Neurotrophic factor assay
US20010023241A1 (en) 1998-02-04 2001-09-20 Sliwkowski Mark X. Use of heregulin as a growth factor
AUPP785098A0 (en) 1998-12-21 1999-01-21 Victor Chang Cardiac Research Institute, The Treatment of heart disease
US6635249B1 (en) 1999-04-23 2003-10-21 Cenes Pharmaceuticals, Inc. Methods for treating congestive heart failure
ITMI20011057A1 (it) 2001-05-22 2002-11-22 Bracco Imaging Spa Preparazione ed uso di peptidi ciclici e ramificati e loro deriati marcati come agenti terapeutici agonisti o antagonisti della colecistochi
AU2002304965A1 (en) 2002-05-24 2003-12-12 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
US7241392B2 (en) 2004-09-09 2007-07-10 Dresser-Rand Company Rotary separator and method
US20070213264A1 (en) 2005-12-02 2007-09-13 Mingdong Zhou Neuregulin variants and methods of screening and using thereof
JP5738516B2 (ja) 2005-12-30 2015-06-24 ゼンサン （シャンハイ） サイエンス アンド テクノロジー リミテッド 心機能改善のためのニューレグリンの徐放
EP2328606B1 (de) 2008-08-15 2016-10-05 Acorda Therapeutics, Inc. Zusammensetzungen und verfahren zur behandlung in nicht-akuten phasen nach einer neurologischen cns-verletzung
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
EP2999499B1 (de) 2013-05-22 2019-07-17 Zensun (Shanghai) Science & Technology, Co., Ltd. Verlängerte freisetzung von neuregulin zur behandlung von herzinsuffizienz

Also Published As

Publication number Publication date
JPH06507544A (ja) 1994-09-01
DK0579640T3 (da) 2002-11-11
EP0579640A1 (de) 1994-01-26
GB9107566D0 (en) 1991-05-29
AU1450992A (en) 1992-11-17
EP0579640B1 (de) 2002-07-24
DE69232693T2 (de) 2003-04-03
CA2108119A1 (en) 1992-10-11
KR100274305B1 (ko) 2000-12-15
DE69232693D1 (de) 2002-08-29
AU6808396A (en) 1997-01-16
AU703772B2 (en) 1999-04-01
WO1992018627A1 (en) 1992-10-29
CA2108119C (en) 2009-06-30
IE921062A1 (en) 1992-10-21
PT100344A (pt) 1993-07-30
ZA922441B (en) 1992-11-25
PT100344B (pt) 1999-08-31

Similar Documents

Publication Publication Date Title
DE69232693D1 (de) Glialmitogene faktoren, ihre herstellung und verwendung
ATE139261T1 (de) Muteine des menschlichen erythropoetins, ihre herstellung und ihre verwendung
DE69215434D1 (de) 1,3,5-Triazinderivate, ihre Herstellung und ihre Verwendung als Lichtschutzmittel
DE69019550D1 (de) Piperidin-Derivate, ihre Herstellung und ihre Verwendung.
DE3885534D1 (de) Arylphosphorderivate, ihre Herstellung und Verwendung.
DE69008454D1 (de) Nitrolsothiolderivate, ihre Herstellung und Verwendung.
ATE88087T1 (de) Chitosan enthaltendes kosmetisches praeparat.
AU612172B2 (en) 5-amino or substituted amino 1,2,3-triazoles useful as antiproliferative agents
DE69204290D1 (de) Verwendung von 1,2,2,3,3-pentafluorpropan.
DE59208576D1 (de) 3-Isoxazolylphenylverbindungen, ihre Herstellung und ihre Verwendung
DE59409541D1 (de) Bicyclen-derivate, ihre herstellung und verwendung
DE69204909D1 (de) Amino-Urazilderivate, deren Herstellung und Verwendung.
DE58908788D1 (de) Modifizierte Blockpolymerisate, ihre Herstellung und Verwendung.
DE59606806D1 (de) Polymerholz-formkörper, ihre herstellung und verwendung
ATE113591T1 (de) 4-benzyl-5-phenyl-2,4-dihydro-3h-1,2,4-triazol- - one und ihre verwendung als antikonvulsiva.
DE68919259D1 (de) N-Phenylimide, ihre Herstellung und Verwendung.
CA2001782A1 (en) 3-(3-propan-2-ylphenyl) butanal and 3-(3-propen-2-ylphenyl) butanal and their use as odorants
DE59203456D1 (de) Flüchtige Inhalationsnarkotika enthaltende Liposomen, ihre Herstellung und Verwendung.
DE58906618D1 (de) Strobilurinderivate, ihre Herstellung und Verwendung.
ATE132500T1 (de) 24r-scymnol, herstellung und verwendung
DE69212484D1 (de) Herstellung von 1,1,1-trifluoro-2-chloroethan und/oder 1,1,1,2-tetrafluoroethan
ATE165381T1 (de) Kondensations- und additionspolymere mit n,n'- verbrückten bis-tetramethylpiperidinyloxy- gruppierungen
ATE128867T1 (de) Verwendung von 3-aryl-5-alkylthio-4h-1,2,4- triazolen zur behandlung von überreflexen infolge von rückenmarkstrauma.
DE69116057D1 (de) Mikrobische Herstellung des 13-beta-13-deoxy-22,23,-dihydroavermectin-Bla/B1b-Aglycons
DE3878988D1 (de) 1,2-di(4-isobutylphenyl)aethylen, dessen herstellung und verwendung als zwischenprodukt.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0579640

Country of ref document: EP